A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.

The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.

Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.

Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.